Pergonal

Quick links to important sections

Pergonal

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pergonal

Property Description
Active ingredient Menotropin (hMG)
Form Powder for injection
Pharmacological class Gonadotropin; Fertility Agent
Common use Hormonal support for reproductive processes
Origin Biological (purified from postmenopausal urine)

What Type of Medicine is Pergonal (Menotropin)?

Pergonal is an injectable pharmaceutical preparation and a well-recognized fertility agent that belongs to the high-level Gonadotropin pharmacological class. Its active substance is Menotropin, formally classified as Human Menopausal Gonadotropin (hMG). This classification identifies it as a medication that directly influences the function of the gonads. Pergonal is a prescription-only product whose efficacy has been clinically recognized for decades in addressing certain forms of infertility.

Composition and Origin: Is Pergonal Natural or Synthetic?

Pergonal is a medicine of biological origin because the Menotropin active ingredient is extracted and highly purified from a natural source: the urine of postmenopausal women. This process results in a combination product that inherently contains the activity of both Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH). This dual hormonal profile is a key differentiator from single-hormone synthetic gonadotropin preparations. The medication is supplied as a sterile powder for injection, a form necessary to ensure the protein hormones are not inactivated by the digestive system.

General Purpose: What Does Pergonal Help to Achieve?

The general therapeutic purpose of Pergonal is to provide necessary hormonal support to individuals unable to produce adequate levels of FSH and LH naturally. By supplementing both hormones, the medicine supports the initial and advanced stages of the reproductive process. A typical, neutral use scenario involves providing hormonal stimulation to support ovarian follicular development in women or to promote spermatogenesis (sperm production) in men, thereby correcting the hormonal signal required for successful reproductive function.

What side effects are possible with Pergonal?

Possible side effects and safety information

The safety profile for menotropins (Pergonal) is defined by regulatory bodies through specific frequency classifications and system-organ-class groupings of documented adverse reactions. This classification strictly outlines the possible effects observed in clinical use.


Adverse Reactions by Frequency and System

The most frequently classified serious adverse reaction is Ovarian Hyperstimulation Syndrome (OHSS), which is documented as Very Common (may affect more than 1 in 10 people). Other very common reactions include localized injection site reactions such as pain or inflammation.

Reactions classified as Common (may affect up to 1 in 10 people) generally affect the Gastrointestinal System (e.g., abdominal pain, nausea, abdominal distension) and the Nervous System (e.g., headache).


Serious Safety Considerations

Official labeling emphasizes the risk of severe OHSS, which can lead to rapid fluid accumulation and potentially life-threatening complications. Documented serious adverse reactions also involve the Vascular System, specifically the risk of thromboembolic events (blood clots), which can occur with or separate from OHSS. Other serious, though less frequent, risks include ovarian torsion and specific risks related to pregnancy outcomes, such as ectopic pregnancy.


Safety Restrictions and Population Notes

The medicine is subject to formal safety restrictions (contraindications). These legally prohibit its use in individuals with specific pre-existing conditions, including tumors of the pituitary gland or hypothalamus, unexplained uterine bleeding, and certain types of ovarian failure. For men receiving menotropin, documented side effects are distinct and include the potential for gynecomastia. The risk of OHSS is officially documented as being associated with the initial phase of ovarian stimulation.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Pergonal (Menotropin) defines the critical overdose scenario as the potential for Ovarian Hyperstimulation Syndrome (OHSS), a severe, life-threatening exaggeration of the hormonal effect.

Documented Clinical Manifestations

Over-stimulation is primarily recognized by the development of OHSS. Documented clinical signs include severe pelvic pain, rapid or excessive weight gain, abdominal distension, nausea, vomiting, and oliguria (decreased urine output). Physiologically, severe cases may involve hemoconcentration, hypovolemia, and electrolyte imbalances.

Severe Outcomes and Emergency Actions

Severe OHSS can progress rapidly, leading to documented systemic complications such as thromboembolic events (e.g., pulmonary embolism, cerebral vascular occlusion) and acute pulmonary distress. The severity of OHSS is noted to be more common, more severe, and more protracted if pregnancy occurs.

Regulatory documents mandate that users seek immediate medical attention or call a healthcare professional right away if severe symptoms occur, such as difficulty breathing, severe pain, or decreased urination. Hospitalization is required for severe OHSS. Management is defined as symptomatic and supportive treatment, focusing on fluid and electrolyte management, as no specific antidote is known.

Therapeutic Uses of Pergonal

What Pergonal Treats: Main Uses and Benefits

Pergonal (Menotropins) is commonly used within the therapeutic domain of infertility treatment, generally applied to manage symptoms related to systemic imbalance that interfere with daily functioning. The medication is applied in situations where additional symptomatic support is needed for conditions related to infertility.

The medication is commonly used to address the symptom cluster of ovulatory dysfunction (absent or irregular egg release), is relevant for easing symptoms associated with conditions that involve episodic or fluctuating manifestations (relevant in clinical settings like IVF and IUI), and helps manage hormone-related male factor infertility.

The medication is considered relevant, as “it plays a role in managing symptoms related to heightened physiological activity, which supports the patient during difficult episodes.” It is applicable across domains where additional symptomatic support is needed.

Quick Fact: Support for Symptomatic Management Pergonal is used to help with symptom clusters that may become intense or disruptive, assisting with maintaining functional stability during symptomatic phases.

Eligibility and Restrictions for Use

Pergonal (menotropins) is a gonadotropin medicine used to stimulate the ovaries. Official regulatory documents define clear populations who must not use this medicine.

Contraindicated Populations

Use is contraindicated (prohibited) in women who are pregnant or breast-feeding. It is also prohibited for both men and women with:

  • Prior hypersensitivity or allergic reactions to menotropins.
  • Tumors of the pituitary gland or hypothalamus.
  • Sex hormone-dependent tumors of the reproductive tract, such as ovarian, uterine, or mammary carcinoma.
  • Abnormal uterine bleeding of undetermined cause.

Other Restrictions and Limitations

Women should not use Pergonal if they have primary ovarian failure (indicated by high FSH levels), or if they have an ovarian cyst or enlargement not due to Polycystic Ovary Syndrome (PCOS). The medicine is also not indicated in the presence of uncontrolled non-gonadal endocrinopathies (like thyroid or adrenal disorders).

Use has not been established in pediatric and geriatric populations. Patients with a known risk for thrombosis must be carefully evaluated due to potential risks. Treatment is generally restricted to patients whose infertility is not due to structural defects incompatible with pregnancy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction scope

Property Official Regulatory Finding
Medicinal product categories with documented interactions Other Gonadotropins and Human Chorionic Gonadotropin (hCG) (used sequentially).
Specific interacting medicines (if explicitly listed) Urofollitropin and Human Chorionic Gonadotropin (hCG).
Mechanistic basis of interactions (only if stated in label) Pharmacodynamic interaction (additive effect) and Physiological/Procedural Constraint (hCG administration based on end-organ response).
Timing-based interaction rules (if applicable) hCG must be administered one day following the last dose of Menotropins.
Population-specific interaction notes (if applicable) The relevance of interactions has not been established in women with renal or hepatic insufficiency.
Interaction-related restrictions The co-administration of Menotropin with another purified FSH product is restricted by a mandatory total daily dose limit. Administration of hCG is restricted (contraindicated) if abnormal ovarian enlargement is evident.

Interaction classifications (high-level)

Property Official Regulatory Finding
Interaction severity classification (as defined in official documents) Includes both Procedural Restrictions (timing rules) and a Contraindicated Combination (hCG when abnormal ovarian enlargement is present).
Regulatory basis U.S. Food and Drug Administration (FDA) Prescribing Information.
Interaction-context constraints (as defined in official documents) The primary constraint is the lack of documented human pharmacokinetic interaction studies in the official labeling.

Resulting interaction structure

Official interaction statements:

  • No specific drug–drug interaction studies have been conducted for menotropins in humans, resulting in an absence of documented pharmacokinetic (CYP-mediated or transporter) interactions.
  • Co-administration with other Gonadotropins (e.g., Urofollitropin) is subject to a mandatory total combined daily dose limit.
  • The use of hCG requires sequential administration, and its administration is prohibited (contraindicated) if there is evidence of abnormal ovarian enlargement.
  • Official regulatory sources do not document any specific, clinically significant interactions with food, alcohol, or herbal products.

Connection to the overall interaction profile: The regulatory interaction profile for Pergonal is defined by the explicit absence of documented pharmacokinetic interaction data, as noted in the official prescribing information. Consequently, the established interaction constraints are limited to pharmacodynamic rules for co-administering other gonadotropins and mandatory procedural restrictions governing the sequential use of Human Chorionic Gonadotropin (hCG). This structure solely reports the official label requirements.

Mechanism of Action

Direct Gonadotropin Receptor Activation

Pergonal, a source of menotropins, functions as a direct agonist for the Follicle-Stimulating Hormone Receptor (FSHR) and the Luteinizing Hormone/hCG Receptor (LHCGR) located primarily on gonadal cells. By binding to these receptors, the drug initiates intracellular signaling cascades that are associated with the recruitment and initial growth of ovarian follicles.


Coordinated Gonadal Steroidogenesis

The combined FSH and LH activities drive the production of sex steroids via the two-cell, two-gonadotropin pathway in the ovary. The FSH activity promotes the conversion of androgens into estradiol by inducing aromatase synthesis in granulosa cells, while the LH activity stimulates androgen precursor production in theca cells. The resulting increase in local sex steroids is a physiological effect that involves endometrial proliferation and alters the state of the reproductive tract.


Influencing Final Follicular Maturation

The drug's LH component further acts to influence the late-stage development of the dominant follicle. This mechanism facilitates the processes associated with oocyte final competence and directly involves the luteinization of granulosa cells and the subsequent formation of the corpus luteum.

Dosage and Administration Information

How Pergonal is Used: Official Administration Guidelines

Pergonal (menotropins) is administered according to a specific, sequential protocol strictly detailed in prescribing information, defining its route, dose, and duration of use.


Administration Scope

Category Official Use Guideline
Route of Administration The product is a lyophilized powder that requires reconstitution and is administered by Subcutaneous (SC) or Intramuscular (IM) injection.
Dosing Regimens Treatment is initiated with an approved daily dose, typically ranging from 150 IU to 225 IU daily for controlled ovarian hyperstimulation. The daily dose may be adjusted, but must not exceed the defined maximum dose of 450 IU.
Preparation & Use The powder must be reconstituted immediately prior to use with the supplied diluent, and the resulting solution must be visually clear and colorless.
Age-Group Rules Use is not recommended in pediatric patients.

Instruction Classifications (High-Level)

Category Classification of Use
Method Type Parenteral (Injectable).
Frequency Pattern Once daily for the duration of the stimulation phase, followed by a separate agent.
Use-Context Constraints Structured as a fixed-duration course that mandates administration of a final trigger dose (e.g., Human Chorionic Gonadotropin (hCG)) as the subsequent step.

Resulting Procedural Structure

The official step sequence involves the reconstitution of the powder, daily SC or IM administration of the titrated dose, and then cessation of menotropin followed immediately by the single injection of hCG. Dose adjustments must be conservative and must not occur more frequently than every two days, limiting the maximum duration of menotropin injections to around 12 to 20 days depending on the specific regimen. These labeled instructions establish menotropin as a managed, short-term component of a larger, required hormonal protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pergonal (Menotropins)


Evidence for Use in Ovulation Induction (OI)

The research exploring Pergonal (menotropins) for Ovulation Induction (OI) focuses primarily on Adult Women evaluated for anovulatory infertility who demonstrated residual ovarian function. This section will summarize the available evidence from Randomized Controlled Trials (RCTs) and comparative studies.

Researchers studied the use of hMG in women with anovulatory infertility. The main outcomes examined in these studies include ovulation rate, clinical pregnancy rate, and live birth rate. Studies monitored physiological measures such as Estradiol levels and the number of developing ovarian follicles. The research highlights changes measured during the study period and reports patterns observed regarding the timing and frequency of ovulation in the studied cycles.

Evidence for Use in Assisted Reproductive Technology (ART) Cycles

This section covers the research focused on using Pergonal for Controlled Ovarian Stimulation (COS) as part of procedures like In Vitro Fertilization (IVF). It outlines the types of multicenter trials and comparative studies conducted to evaluate the outcomes related to multiple follicular development.

Studies were conducted during periods of increased symptom activity (the stimulation phase) and research examined outcomes related to systemic or functional imbalance. The primary endpoints monitored included the number of oocytes retrieved, embryo quality, Ongoing Pregnancy Rate (OPR), and Live Birth Rate. The data show patterns related to the number of eggs that were retrieved following the short-term stimulation. Reported outcomes were short-term and based on comparisons to other similar hormonal therapies.

Evidence for Use in Male Fertility (Spermatogenesis)

This block summarizes the research available on Pergonal for men with hormonal conditions that cause Male Factor Infertility, specifically was studied for spermatogenesis (sperm production). The available evidence is derived from small clinical trials and observational cohort studies that observed responses over defined time intervals. Studies monitored physiological outcomes such as sperm concentration, sperm motility, and changes in serum Testosterone levels over a period of many months.


What is Still Uncertain About Pergonal Research

Evidence quality varies across studies, particularly in older cohorts or those with small sample sizes. Comparative evidence is lacking for some protocols and subgroup findings are uncertain. Data are still emerging regarding long-term outcomes and the patterns related to functional stability over decades. Research provides context but not individual predictions, and certainty remains low in areas where studies are limited.

Key Studies & References

  1. MENOPUR (menotropins for injection) [NIH DailyMed Label]
  2. The Gonadotropin Combinations in ART: A Systematic Review and Meta-Analysis
  3. Induction of spermatogenesis in men with gonadotrophin deficiency [Review]

Frequently Asked Questions (FAQ)

Common questions about Pergonal (FAQ)

Q: Is Pergonal the same thing as Menopur?

Pergonal is considered a historical trade name for a medicine containing the active ingredient menotropins, also known as Human Menopausal Gonadotropin (hMG). Menopur is a currently marketed trade name for a menotropins product. Official regulatory documents list both brand names as containing the same active ingredient.

Q: Does Pergonal help with both male and female infertility?

Yes, official regulatory documents describe the use of menotropins for both men and women. In women, the medicine is described as supporting ovarian follicular development and ovulation induction. In men, it is used to stimulate the production of sperm (spermatogenesis) when their infertility is linked to specific hormonal deficiencies.

Q: What is the difference between Pergonal and FSH injections?

Pergonal (menotropins) is classified as a Human Menopausal Gonadotropin (hMG) which is distinct because it contains the activity of both the Follicle-Stimulating Hormone (FSH) and the Luteinizing Hormone (LH). In contrast, dedicated FSH injections contain only the FSH activity. This dual hormonal profile is noted in the official product information.

Q: Can I drink alcohol while I am using Pergonal?

Official regulatory prescribing information for menotropins does not document specific, clinically significant interactions with alcohol. The regulatory label advises consulting a healthcare professional for guidance regarding alcohol consumption during treatment.

Q: Do any foods or vitamins interact with Pergonal?

Official regulatory prescribing information for menotropins does not document specific, clinically significant interactions with food, herbal products, or vitamins. The established interaction constraints are primarily limited to other hormonal therapies used in the reproductive protocol.

Q: Is it true that Pergonal is made from urine?

The active ingredient in Pergonal, menotropins, is a natural product that is extracted and highly purified from the urine of postmenopausal women. The purification process results in the final, sterile pharmaceutical product that is administered by injection.

Q: Why are people often confused about the name Pergonal and hMG?

The confusion arises because Pergonal is a historical brand name, while hMG stands for Human Menopausal Gonadotropin, which is the formal, generic class name for the active ingredient (menotropins). They both refer to the same type of injectable medicine used in fertility protocols.

Q: How quickly does Pergonal start to work?

The medicine is designed to act rapidly. Studies show the FSH component reaches measurable levels in the blood within approximately 4 hours after injection. While the drug components are present quickly, the full clinical effect on ovarian follicles takes days of continued administration to become noticeable through monitoring.

Q: Are there any long-term effects of taking Pergonal?

The treatment course for menotropins is short-term, and official labeling does not define specific long-term effects decades after use. However, regulatory warnings note that the potential risk of developing ovarian tumors following fertility treatments using this class of medicine has not been fully established and should be considered by the prescribing physician.

Q: Does Pergonal cause weight gain?

While weight gain is not listed as a common, isolated side effect, rapid weight gain is specifically listed in regulatory documents as a potential symptom associated with the serious adverse reaction Ovarian Hyperstimulation Syndrome (OHSS). This should be monitored as directed by a healthcare provider.

Q: Does Pergonal cause headaches?

Yes, regulatory documents list headache as a commonly reported adverse reaction. This is generally classified as common, meaning it may affect up to 1 in 10 people.

Q: Does Pergonal cause stomach cramps?

Regulatory documents list abdominal issues such as stomach cramps, fullness, and abdominal pain as commonly reported adverse reactions that may occur during treatment.

Q: Can men use Pergonal, and for what reason?

Menotropins are officially approved for use in men with certain hormonal deficiencies. The purpose is to stimulate the production of sperm (spermatogenesis) when their testes are functional. Official safety information for men also notes the potential for a side effect called gynecomastia.

Q: Is Pergonal safe to use with common pain relievers?

Official regulatory documents state that specific drug–drug interaction studies have not been conducted in humans, so there is an absence of documented pharmacokinetic (how the drug is metabolized) interactions with general pain relievers. You should always inform your physician of all medicines you are taking.

Q: How long after stopping Pergonal does it stay in your system?

The active components of the medicine have different biological half-lives. The FSH component is reported to have a half-life of around 70 hours after the last dose. This means the activity of the medicine gradually decreases over several days following the final injection.

Q: What should I do if I accidentally take too much Pergonal?

Regulatory documents do not describe specific steps for overdose management. If there is concern about administering too much of the medicine, it is recommended to seek immediate professional medical assistance. Overadministration may increase the serious risk of Ovarian Hyperstimulation Syndrome (OHSS).

Q: Can Pergonal increase the chance of multiple births?

Yes, regulatory warnings state that the use of menotropins increases the risk of a pregnancy resulting in multiple births (such as twins or triplets). This risk is associated with ovarian stimulation leading to the development of multiple follicles.

Q: Is the medication Pergonal still available today?

Pergonal is a historical trade name and is no longer commercially marketed under that specific brand. The active ingredient, menotropins, remains available under different current brand names, such as Menopur.

Q: What is the shelf life of Pergonal?

The unopened powder product typically has a manufacturer-assigned expiration date (shelf life) of around 24 months from the date of manufacture when it is stored according to the official temperature and light-protection recommendations. The reconstituted liquid must be used immediately and any remaining solution must be discarded.

Q: How does my age affect the effectiveness of Pergonal?

Official reports on clinical research indicate that patient age 35 years and older has been shown to be a factor associated with an increased risk of spontaneous first-trimester miscarriage in women treated with menotropins. Age is one of the patient factors considered when physicians plan and monitor treatment.

Q: What is the risk of having a miscarriage after using Pergonal?

The official regulatory label states that the rate of miscarriage (spontaneous abortion) is higher in pregnancies resulting from menotropins/hCG treatment than in the general population. This is listed as a warning and is a factor monitored during the early stages of pregnancy.

How should Pergonal be stored and disposed of?

How to Store and Dispose of Pergonal?

The storage and disposal of Pergonal (menotropins for injection) must align strictly with the official regulatory labeling.


Storage Requirements

Product State Requirement
Unopened Powder Must be stored at controlled room temperature (15^circC to 30^circC / 59^circF to 86^circF). The product must be protected from light and moisture and must not be frozen.
Reconstituted Solution Must be used immediately after mixing. Any unused solution must be discarded.
General Rule Store the product in its original container and keep it out of the sight and reach of children.

Disposal Instructions

Expired or unused medication must be disposed of according to local regulatory guidelines. Do not dispose of the product by flushing it down the toilet or throwing it in the household trash. Used needles and syringes (sharps) must be placed immediately into an FDA-cleared, puncture-resistant sharps disposal container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pergonal found in:

A-Z Index: